Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Organ Preservation in Early Rectal Cancer Patients
NCT03548961Phase 2Active, not recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- May 2018
- Primary completion
- Apr 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid and oxaliplatin in rectal cancer, sponsored by Fox Chase Cancer Center. Primary endpoint: Number of patients whose tumor can be resected by local excision with negative margins at 3 months. Started May 2018; status: active, not recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03548961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548961.